No abstract

In a multi-centre study strontium-89 was shown to be effective in relieving bone pain from prostatic carcinoma in patients who had failed conventional therapies. Of 83 patients assessed at 3 months, following the administration of a dose of at least 1.5 MBq/kg, 75% derived benefit and 22% became pain free. Symptomatic improvement usually occurred within 6 weeks and continued for between 4 and 15 months (mean 6 months). Based on the dose estimation part of this study the recommended dose of strontium-89 is 150 MBq. Toxicity was low, provided platelet levels were above 100 x 10(9) l-1 at the time of treatment. Repeat treatments with strontium-89 may be given at intervals of not less than 3 months. Strontium-89 is administered intravenously on an out-patient basis with no special radiological protection precautions.

No abstract

SUMMARYThis review summarises the present knowledge concerning the decomposition by selflirradiation of compounds labelled with the radioisotopes, carbon-14, hydrogen-3 (tritium), sulphur-35, selenium-75, chlorine-36, phosphorus-32, iodine-125, iodine-131, cobalt-57 and cobalt-58. A discussion of the methods which can be used for the control of this decomposition is also included.

No abstract